Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03580655 · OUTCOME

Overall Survival (OS)

(PATHFINDER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis · Source last updated 2026-04-24

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
Months
Interval / dispersion
95% Confidence Interval
Time frame
Baseline through Month 65

What was measured

OS was defined as time from first dose to the time of death due to any cause. Participants who were known to be alive or are lost to follow-up were censored at the last time point they were known to be alive.

Analysis population: Safety Population: all participants who received ≥1 dose of avapritinib.

Groups in this outcome

Avapritinib

Avapritinib was administered once daily as an immediate-release tablet, orally, in 28-day cycles.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Avapritinib107

Reported measurements

Source class 1
Values in Months · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Avapritinib61.6Not reported60.0NAValues were non-estimable (insufficient number of participants with events).
Complete source fields
classes
  1. categories
    1. measurements
      1. comment
        Values were non-estimable (insufficient number of participants with events).
        group Id
        OG000
        lower Limit
        60.0
        upper Limit
        NA
        value
        61.6
denoms
  1. counts
    1. group Id
      OG000
      value
      107
    units
    Participants
description
OS was defined as time from first dose to the time of death due to any cause. Participants who were known to be alive or are lost to follow-up were censored at the last time point they were known to be alive.
dispersion Type
95% Confidence Interval
groups
  1. description
    Avapritinib was administered once daily as an immediate-release tablet, orally, in 28-day cycles.
    id
    OG000
    title
    Avapritinib
param Type
MEDIAN
population Description
Safety Population: all participants who received ≥1 dose of avapritinib.
reporting Status
POSTED
time Frame
Baseline through Month 65
title
Overall Survival (OS)
type
SECONDARY
unit Of Measure
Months

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice